化湿解毒方治疗新型冠状病毒肺炎湿热郁肺证的临床研究

目的观察化湿解毒方治疗新型冠状病毒肺炎湿热郁肺证患者的临床疗效及对相关炎症指标表达影响和CT影像学改变。方法收集确诊轻型及普通型新型冠状病毒肺炎湿热郁肺证患者63例,分为治疗组44例,对照组19例,对照组口服阿比多尔、洛匹那韦/利托那韦,干扰素雾化,治疗组在对照组基础上口服化湿解毒方。于治疗前、后进行中医证候评分及外周血的白细胞计数(WBC),淋巴细胞比值(LYM%),中性粒细胞比值(NEU%),降钙素原(PCT),C反应蛋白(CRP),D-二聚体(D-Dimer)表达,肺部CT渗出吸收率等比较。结果治疗10d后,治疗组患者中医证候积分明显减轻,总有效率高于对照组(P<0.05);2组患者CRP、PCT、D-二聚体水平与治疗前比较均有显著下降(P<0.05);治疗后治疗组与对照组比较,CRP和PCT表达有显著差异(P<0.05),D-二聚体表达差异无统计学意义(P>0.05);胸部CT渗出吸收率比较,差异有统计学差异(P<0.05)。结论早期及时使用化湿解毒方可以减轻新型冠状病毒肺炎湿热郁肺证患者的症状,调控相关炎症指标的表达,促进肺部渗出的吸收,有较好的临床疗效。

Clinical Study on Huashijiedu Decoction in Treating Patientswith Damp-heat Stagnation Lung Syndrome of New Coronavirus Pneumonia

Objective:To observe the clinical effect of Huashijiedu Decoction in the treatment of patients with damp-heat stagnation of lung syndrome of new coronavirus pneumonia and its influence on the expression of related inflammation indicators and CT imaging changes.Methods:63 patients with diagnosed mild and common new coronavirus pneumonia with damp-heat stagnation syndrome were collected and divided into a treatment group with 44 cases and a control group with 19 cases.The control group was given oral abidol,lopinavir/ritonavir with interferon nebulization and the treatment group was added with oral Huashijiedu Decoction on the basis of the control group.The TCM syndrome score and peripheral blood white blood cell count(WBC),lymphocyte ratio(LYM%),neutrophil ratio(NEU%),procalcitonin(PCT),C-reactive protein(CRP),D-Dimer(D-Dimer)expression,lung CT exudation and absorption rate were compared before and after treatment.Results:After 10-day treatment,the TCM syndrome scores of the patients in the treatment group were significantly reduced,and the total effective rate was higher than that in the control group(P<0.05).The levels of CRP,PCT,and D-dimer in the two groups were significantly decreased when compared with those before treatment(P<0.05).After treatment,the expression of CRP and PCT was significantly different between the treatment group and the control group(P<0.05).There was no significant difference in the expression of D-dimer(P>0.05)and the comparison of chest CT exudation and absorption rate showed the difference was statistically significant(P<0.05).Conclusion:The early and timely use of Huashijiedu Decoction can reduce the symptoms of patients with the damp-heat stagnation syndrome of new coronavirus pneumonia,regulate the expression of related inflammatory indicators,and promote the absorption of pulmonary exudate,which has a good clinical effect.